cancer vaccine

NANTES, France — September 23, 2026 OSE Immunotherapeutics announced that topline results from the Combi-TED Phase 2 trial of...

Rio Rancho, New Mexico, August 19, 2026 NTx Bio is advancing the manufacturing infrastructure supporting personalized cancer vaccines through...

BETHESDA, Md., July 2, 2026 Northwest Biotherapeutics announced that its Chief Technical Officer, Dr. Marnix Bosch, will deliver a...

SAN JOSE, Calif., June 29, 2026 Anixa Biosciences, Inc. announced that the Korean Ministry of Intellectual Property (MOIP) has...

SAN JOSE, Calif., June 11, 2026 Anixa Biosciences, Inc. announced that two of its clinical-stage cancer immunotherapy programs will...

NANTES, France, May 22, 2026 OSE Immunotherapeutics announced positive topline results from the Phase 2 TEDOVA trial evaluating Tedopi®...

Vancouver, British Columbia | January 20, 2026 — BioVaxys Technology Corp. reported positive Phase 1B/2 clinical results from its...